<DOC>
	<DOCNO>NCT00003157</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Radiation therapy use high-energy x-rays damage tumor cell . Combining radiation therapy chemotherapy may kill tumor cell . PURPOSE : Phase I trial study effectiveness radiation therapy plus chemotherapy treating patient cancer pancreas stomach .</brief_summary>
	<brief_title>Radiation Therapy Chemotherapy Treating Patients With Cancer Pancreas Stomach</brief_title>
	<detailed_description>OBJECTIVES : I . Determine maximum tolerate dose gemcitabine cisplatin administer standard course radiation therapy patient unresectable locally recurrent pancreatic gastric cancer . II . Describe tolerance gemcitabine , cisplatin , radiation therapy patient population . III . Seek preliminary evidence therapeutic activity regimen patient population measure survival . OUTLINE : This dose escalation study . Patients undergo radiotherapy tumor lymph node , follow decrease radiotherapy tumor alone . Radiation therapy administer total 5.5 week . Patients receive intravenous gemcitabine twice weekly Tuesday Friday first 3 week radiotherapy . Cisplatin administer intravenously twice weekly follow gemcitabine therapy . Three patient treat dose level . Dose escalation occur patient give dose level complete radiotherapy return 4 week follow . The dose limiting toxicity ( DLT ) define dose least 2 6 patient experience unacceptable toxic effect . The maximum tolerate dose define dose 1 6 patient experience DLT . Patients exhibit stable disease remain therapy disease progression intolerable toxic effect . Patients experience toxic effect disease progression retreat low dose . Patients follow every 3 month first 2 year every 6 month next year .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven unresectable ( include incomplete resection ) locally recurrent pancreatic gastric cancer No evidence metastasis outside plan radiation field No cystadenocarcinoma pancreas pancreatic tumor neuroendocrine origin PATIENT CHARACTERISTICS : Age : 18 Performance Status : ECOG 01 Life Expectancy : Not specify Hematopoietic : Absolute neutrophil count least 2,000/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin within normal limit Alkaline phosphatase great 3.0 time upper limit normal ( ULN ) AST great 3.0 time ULN Renal : Creatinine great 1.3 time ULN Other : Not pregnant nursing Fertile patient must use effective contraception No significant infection medical illness No significant nausea vomit At least 1200 calorie per day oral nutrition PRIOR CONCURRENT THERAPY : Biologic therapy : No prior concurrent biologic therapy Chemotherapy : No prior concurrent chemotherapy Endocrine therapy : Not specify Radiotherapy : No prior radiotherapy ( except focal field skin cancer overlap plan radiotherapy field ) Surgery : At least 21 day since laparotomy surgery</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>stage IV gastric cancer</keyword>
	<keyword>recurrent gastric cancer</keyword>
	<keyword>recurrent pancreatic cancer</keyword>
	<keyword>stage IV pancreatic cancer</keyword>
</DOC>